Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

clinical trial

Details

Instance of: clinical trial
Country: United States
Main subject: Mesenchymal stem cells, sclerosis, multiple sclerosis
maximum age: 70
minimum age: 18
research site: Icahn School of Medicine at Mount Sinai
study type: expanded access
title: Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally

Nothing in the MetaHistoryBook collection references this item yet.